

BIOPHYTIS: enrollment of the first subjects in the pharmacokinetics study on Sarcopenia

Romainville, 26 August 2016, 08:00 – BIOPHYTIS (Alternext Paris: ALBPS), a biotechnology company specialized in development of drug candidates to treat aging diseases, announces the enrollment of the first volunteers in the pharmacokinetics study SARA-PK. The first step of the study will allow to compare pharmacokinetics and safety of Sarconeos, after escalating single dose administrations in elder and young healthy volunteers.

Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, declares: *“The start of the SARA-PK clinical study only four months after the Belgian Federal Agency for Medicines and Health Products’ (FAMHP, Belgian Drug Agency) scientific advice, demonstrates the responsiveness of Biophytis’ clinical development team. This study will potentially allow to adjust the two doses of Sarconeos that will be compared in the phase 2b international study, SARA-INT, to complete the clinical and regulatory filing and to start the study in 2017, as soon as the authorizations are granted in Europe and in the US.”*

ABOUT THE SARA-PK STUDY: Approved by the Belgian Federal Agency for Medicines and Health Products (FAMHP) and the Ethics Committee in Antwerp, the SARA-PK study will allow for qualification of pharmacokinetics and safety of Sarconeos in elderly healthy volunteers (> 65 years old). This study comprises two phases: the first to compare pharmacokinetics in elder and young healthy volunteers after escalating single dose administrations of Sarconeos; the second one to study pharmacokinetics and safety on elder healthy volunteers (30 volunteers) after daily administrations of Sarconeos for 14 days, at 3 doses. The results of the study will complete the clinical and regulatory file for Sarconeos, which is required for authorization to initiate the Phase IIb “SARA INT” clinical study, currently scheduled to start in the first half of 2017 in France, Belgium, Italy and USA.

ABOUT SARCONEOS: Sarconeos is the first representative of a new class of drug candidates, based on the activation of the MAS receptor (major player of the renin-angiotensin system) stimulating anabolism in the muscle, inhibitor of myostatin and favoring muscle mass development in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle and strength, leading to a loss of mobility in elderly people. This new pathology, for which no medical treatment currently exists, was first described in 1993 and just entered the WHO International Classification of Diseases (M62.84), affects more than 50 million people worldwide.

About BIOPHYTIS:

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has discovered and begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing next year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre et Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN: FR0012816825).

For more information: <http://www.biophytis.com>

BIOPHYTIS is eligible for the Equity Saving Plans PEA-PME.

ALBPS
LISTED
ALTERNEXT



Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS' website (www.biophytis.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.

BIOPHYTIS
Stanislas VEILLET

Milestones
Press and investor relations

LifeSci Advisors
Chris MAGGOS

CEO
contact@biophytis.com
Tel : +33 (0) 1 41 83 66 00

Bruno ARABIAN
barabian@milestones.fr
Tel : +33 (0) 1 83 62 34 84
Mob : +33 (0) 6 87 88 47 26

Managing Director, Europe
chris@lifesciadvisors.com
Tel : +41 79 367 6254

Citigate Dewe Rogerson
International press
Laurence BAULT/Antoine DENRY
Laurence.bault@citigate.fr/antoine.denry@citigate.fr
Tel : +33 (0)1 53 32 84 78
Mob : +33(0)6 64 12 53 61